| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pre-Exposure Prophylaxis | 4 | 2019 | 1138 | 1.22 | Why? |
| Anti-HIV Agents | 6 | 2019 | 2209 | 1.12 | Why? |
| Meningitis, Pneumococcal | 1 | 2021 | 35 | 0.88 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 66 | 0.85 | Why? |
| Darunavir | 3 | 2020 | 477 | 0.84 | Why? |
| Sexually Transmitted Diseases | 2 | 2019 | 694 | 0.82 | Why? |
| HIV Infections | 11 | 2021 | 11620 | 0.80 | Why? |
| Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2018 | 3 | 0.78 | Why? |
| Tuberculosis, Meningeal | 1 | 2021 | 100 | 0.78 | Why? |
| Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 26 | 0.76 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.73 | Why? |
| HIV Seropositivity | 2 | 2018 | 320 | 0.73 | Why? |
| Alanine | 4 | 2021 | 5687 | 0.58 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.56 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.55 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.49 | Why? |
| Homosexuality, Male | 3 | 2019 | 1158 | 0.49 | Why? |
| Enterocolitis | 1 | 2013 | 62 | 0.47 | Why? |
| Antimicrobial Stewardship | 1 | 2020 | 931 | 0.47 | Why? |
| Sexual Behavior | 2 | 2019 | 1322 | 0.46 | Why? |
| Germany | 18 | 2021 | 9196 | 0.45 | Why? |
| Immunocompetence | 1 | 2013 | 280 | 0.44 | Why? |
| Emtricitabine | 2 | 2019 | 202 | 0.35 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.35 | Why? |
| Tenofovir | 3 | 2020 | 449 | 0.34 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.32 | Why? |
| Home Care Services | 1 | 2018 | 1351 | 0.31 | Why? |
| Cytomegalovirus Infections | 1 | 2013 | 667 | 0.31 | Why? |
| Adenine | 2 | 2019 | 463 | 0.31 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 952 | 0.29 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.28 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.27 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.26 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.24 | Why? |
| HIV | 2 | 2020 | 1116 | 0.24 | Why? |
| Ritonavir | 1 | 2017 | 4212 | 0.24 | Why? |
| Spirochaetales Infections | 1 | 2021 | 10 | 0.23 | Why? |
| Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.23 | Why? |
| Extravascular Lung Water | 1 | 2021 | 32 | 0.23 | Why? |
| Sulbactam | 1 | 2020 | 37 | 0.22 | Why? |
| Ampicillin | 1 | 2020 | 73 | 0.22 | Why? |
| Brain Abscess | 1 | 2021 | 50 | 0.22 | Why? |
| Anti-Retroviral Agents | 2 | 2019 | 1099 | 0.21 | Why? |
| Antiviral Agents | 4 | 2021 | 41703 | 0.21 | Why? |
| Bile Duct Diseases | 1 | 2019 | 12 | 0.20 | Why? |
| Linezolid | 1 | 2020 | 160 | 0.20 | Why? |
| Glucose Clamp Technique | 1 | 2018 | 39 | 0.19 | Why? |
| Bile | 1 | 2019 | 56 | 0.19 | Why? |
| Extracorporeal Circulation | 1 | 2020 | 130 | 0.19 | Why? |
| Blood Platelets | 2 | 2021 | 1704 | 0.19 | Why? |
| Mountaineering | 1 | 2018 | 20 | 0.19 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
| Asymptomatic Infections | 1 | 2018 | 7218 | 0.18 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.18 | Why? |
| Community-Acquired Infections | 2 | 2021 | 2328 | 0.18 | Why? |
| Hearing Disorders | 1 | 2019 | 62 | 0.18 | Why? |
| Lymphoma, AIDS-Related | 1 | 2017 | 13 | 0.18 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.18 | Why? |
| Cobicistat | 1 | 2019 | 172 | 0.18 | Why? |
| Postural Balance | 1 | 2019 | 144 | 0.18 | Why? |
| Chemotherapy, Adjuvant | 1 | 2021 | 606 | 0.17 | Why? |
| Chlamydia trachomatis | 1 | 2019 | 172 | 0.17 | Why? |
| Infectious Disease Medicine | 1 | 2020 | 311 | 0.17 | Why? |
| Neoplasms, Second Primary | 1 | 2018 | 100 | 0.17 | Why? |
| Enterobacteriaceae Infections | 2 | 2020 | 529 | 0.17 | Why? |
| Vancomycin | 1 | 2020 | 328 | 0.17 | Why? |
| Streptococcal Infections | 1 | 2020 | 255 | 0.17 | Why? |
| Aspergillosis | 1 | 2020 | 264 | 0.16 | Why? |
| Escherichia coli Infections | 1 | 2020 | 348 | 0.16 | Why? |
| Pulmonary Edema | 1 | 2021 | 430 | 0.16 | Why? |
| Adult | 27 | 2021 | 244371 | 0.16 | Why? |
| Drug Administration Schedule | 2 | 2020 | 2324 | 0.16 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.16 | Why? |
| Leg | 1 | 2017 | 142 | 0.16 | Why? |
| Vascular Calcification | 1 | 2020 | 396 | 0.16 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.15 | Why? |
| Carcinoma, Basal Cell | 1 | 2018 | 144 | 0.15 | Why? |
| Fluorenes | 1 | 2016 | 101 | 0.15 | Why? |
| Male | 32 | 2021 | 367725 | 0.15 | Why? |
| Oxazines | 1 | 2017 | 279 | 0.15 | Why? |
| CD4 Lymphocyte Count | 2 | 2019 | 1517 | 0.15 | Why? |
| Humans | 48 | 2021 | 930598 | 0.15 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.15 | Why? |
| Spatial Analysis | 1 | 2021 | 878 | 0.15 | Why? |
| Gonorrhea | 1 | 2019 | 315 | 0.14 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.14 | Why? |
| Syphilis | 1 | 2019 | 318 | 0.14 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.14 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.14 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2017 | 403 | 0.13 | Why? |
| Cholecalciferol | 1 | 2017 | 246 | 0.13 | Why? |
| Benzimidazoles | 1 | 2016 | 275 | 0.13 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 634 | 0.13 | Why? |
| Leukocytes | 1 | 2021 | 1046 | 0.13 | Why? |
| Gambling | 1 | 2017 | 183 | 0.13 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2017 | 669 | 0.13 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.13 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.13 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.12 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.12 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 800 | 0.12 | Why? |
| Sofosbuvir | 1 | 2016 | 518 | 0.11 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.11 | Why? |
| Female | 27 | 2021 | 380317 | 0.11 | Why? |
| Plasma | 2 | 2021 | 1809 | 0.11 | Why? |
| Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.11 | Why? |
| Staphylococcal Infections | 1 | 2020 | 1099 | 0.11 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.11 | Why? |
| Pneumonia | 2 | 2021 | 5652 | 0.11 | Why? |
| Shock, Septic | 1 | 2021 | 1313 | 0.11 | Why? |
| Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.11 | Why? |
| Aged | 20 | 2021 | 215776 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Antifungal Agents | 1 | 2020 | 1828 | 0.10 | Why? |
| Behavior, Addictive | 1 | 2017 | 535 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.10 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.10 | Why? |
| HIV-1 | 3 | 2019 | 3365 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.09 | Why? |
| Ultraviolet Rays | 1 | 2018 | 1272 | 0.09 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.09 | Why? |
| Vitamins | 1 | 2017 | 1208 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2021 | 243684 | 0.09 | Why? |
| Cytomegalovirus | 1 | 2013 | 600 | 0.08 | Why? |
| Hepacivirus | 1 | 2016 | 1509 | 0.08 | Why? |
| Aged, 80 and over | 10 | 2021 | 88759 | 0.08 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.08 | Why? |
| Cohort Studies | 5 | 2020 | 36005 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.08 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Coronary Artery Disease | 1 | 2020 | 2570 | 0.08 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Hepatitis C | 1 | 2016 | 1514 | 0.07 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.07 | Why? |
| Tuberculosis | 1 | 2021 | 2895 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2018 | 1679 | 0.07 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.07 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.07 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.06 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.06 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.06 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.06 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.06 | Why? |
| Psoriasis | 1 | 2017 | 1739 | 0.06 | Why? |
| Occupational Diseases | 1 | 2018 | 2787 | 0.06 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.06 | Why? |
| Substance-Related Disorders | 1 | 2017 | 2038 | 0.06 | Why? |
| Diagnosis, Differential | 2 | 2017 | 7220 | 0.06 | Why? |
| Mesylates | 1 | 2021 | 33 | 0.06 | Why? |
| Thermodilution | 1 | 2021 | 62 | 0.06 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.06 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2021 | 72 | 0.05 | Why? |
| Galactose | 1 | 2021 | 201 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.05 | Why? |
| Granzymes | 1 | 2021 | 197 | 0.05 | Why? |
| Urea | 1 | 2021 | 228 | 0.05 | Why? |
| Mannans | 1 | 2021 | 218 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.05 | Why? |
| Occupational Exposure | 1 | 2018 | 4742 | 0.05 | Why? |
| P-Selectin | 1 | 2021 | 224 | 0.05 | Why? |
| Capillary Permeability | 1 | 2021 | 277 | 0.05 | Why? |
| Hearing Tests | 1 | 2019 | 76 | 0.05 | Why? |
| Esters | 1 | 2021 | 300 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Enterococcus | 1 | 2019 | 73 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| HLA-DR Antigens | 1 | 2021 | 563 | 0.05 | Why? |
| RNA, Viral | 4 | 2020 | 32276 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Anonymous Testing | 1 | 2017 | 2 | 0.04 | Why? |
| Sunscreening Agents | 1 | 2018 | 63 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| Heterosexuality | 1 | 2018 | 148 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
| Guanidines | 1 | 2021 | 499 | 0.04 | Why? |
| Iatrogenic Disease | 1 | 2019 | 304 | 0.04 | Why? |
| Alkaline Phosphatase | 1 | 2017 | 257 | 0.04 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.04 | Why? |
| Interleukin-17 | 1 | 2021 | 602 | 0.04 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.04 | Why? |
| Hypocalcemia | 1 | 2017 | 120 | 0.04 | Why? |
| Drainage | 1 | 2019 | 414 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2019 | 450 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Enterobacteriaceae | 1 | 2019 | 395 | 0.04 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.04 | Why? |
| Holidays | 1 | 2018 | 311 | 0.04 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.04 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Lung | 2 | 2021 | 31049 | 0.03 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.03 | Why? |
| Carbon Dioxide | 1 | 2020 | 917 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Public Health | 1 | 2019 | 16359 | 0.03 | Why? |
| History, 21st Century | 1 | 2020 | 1849 | 0.03 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Practice Guidelines as Topic | 3 | 2021 | 15421 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
| Calcium | 1 | 2017 | 708 | 0.03 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Coronary Angiography | 1 | 2020 | 2275 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 1115 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.03 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.03 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.03 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.03 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.02 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.02 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.02 | Why? |
| Blood Pressure | 1 | 2019 | 2198 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2016 | 7268 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Models, Theoretical | 1 | 2019 | 6659 | 0.01 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.01 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |